1-16 of 16
Karin Vanderkerken
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4110: Identification of tumor peptides for therapeutic mRNA vaccination in a mouse multiple myeloma model

Arne Van der Vreken, Fabien Thery, Sofie Meulewaeter, Karin Vanderkerken, Elke De Bruyne, Kim De Veirman, Lorenzo Franceschini, Rein Verbeke, Francis Impens, Ine Lentacker, Karine Breckpot, Eline Menu
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4110.
https://doi.org/10.1158/1538-7445.AM2024-4110
Published: 22 March 2024
View article titled, Abstract 4110: Identification of tumor peptides for therapeutic mRNA vaccination in a mouse multiple myeloma model
Journal Articles

Abstract 4181: AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in acute myeloid leukemia

Niels Vandewalle, Hatice Satilmis, Emma M. Verheye, Rong Fan, Yanmeng Wang, Timo W. De Groof, Tessa Kerre, Nathan De Beule, Ann De Becker, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Karine Breckpot, Nick Devoogdt, Kim De Veirman
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4181.
https://doi.org/10.1158/1538-7445.AM2024-4181
Published: 22 March 2024
View article titled, Abstract 4181: AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in acute myeloid leukemia
Journal Articles

Abstract 2505: PYCR1 inhibition in multiple myeloma-associated stroma limits tumor growth

Inge Oudaert, Catharina Muylaert, Hatice Satilmis, Sylvia Faict, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Eline Menu
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2505.
https://doi.org/10.1158/1538-7445.AM2023-2505
Published: 04 April 2023
View article titled, Abstract 2505: PYCR1 inhibition in multiple myeloma-associated stroma limits tumor growth
Journal Articles

Abstract LB-117: Role of ectoenzymes CD39 and CD73 in the immune response to multiple myeloma

Rui Yang, Samah Elsaadi, Kristine Misund, Geir Slupphaug, Eline Menu, Carl Hay, Zac Cooper, Karin Vanderkerken, Magne Børset, Anne Marit Sponaas
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): LB-117.
https://doi.org/10.1158/1538-7445.AM2018-LB-117
Published: 01 July 2018
View article titled, Abstract LB-117: Role of ectoenzymes CD39 and CD73 in the immune response to multiple myeloma
Journal Articles

Abstract 2120: Inhibition of multiple myeloma exosomes prevents bone loss and reduces tumor growth

Sylvia T. Faict, Kim De Veirman, Ken Maes, Elke De Bruyne, Roy Heusschen, Jo Caers, Karin Vanderkerken, Rik Schots, Eline Menu
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2120.
https://doi.org/10.1158/1538-7445.AM2018-2120
Published: 01 July 2018
View article titled, Abstract 2120: Inhibition of multiple myeloma exosomes prevents bone loss and reduces tumor growth
Journal Articles

Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression

Eva De Smedt, Ken Maes, Stefaan Verhulst, Hui Lui, Alboukadel Kassambara, Anke Maes, Nicolas Robert, Carlo Heirman, Andrew Cakana, Dirk Hose, Karine Breckpot, Leo A. van Grunsven, Kim De Veirman, Eline Menu, Karin Vanderkerken, Jérôme Moreaux, Elke De Bruyne
Journal: Cancer Research
Cancer Res (2018) 78 (5): 1155–1168.
https://doi.org/10.1158/0008-5472.CAN-17-1544
Published: 28 February 2018
View article titled, Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression
Open the PDF for Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression in another window
Includes: Supplementary data
Journal Articles

Abstract LB-091: Inhibition of Siglec-15 prevents bone loss in a mouse model of multiple myeloma

Gilles B. Tremblay, Anna Moraitis, Karin Vanderkerken, Mario Filion
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): LB-091.
https://doi.org/10.1158/1538-7445.AM2016-LB-091
Published: 15 July 2016
View article titled, Abstract LB-091: Inhibition of Siglec-15 prevents bone loss in a mouse model of multiple myeloma
Journal Articles

Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro, Ex Vivo, and In Vivo in the 5T33MM Mouse Model

Pedram Kharaziha, Hendrik De Raeve, Charlotte Fristedt, Qiao Li, Astrid Gruber, Per Johnsson, Georgia Kokaraki, Maria Panzar, Edward Laane, Anders Österborg, Boris Zhivotovsky, Helena Jernberg-Wiklund, Dan Grandér, Fredrik Celsing, Magnus Björkholm, Karin Vanderkerken, Theocharis Panaretakis
Journal: Cancer Research
Cancer Res (2012) 72 (20): 5348–5362.
https://doi.org/10.1158/0008-5472.CAN-12-0658
Published: 14 October 2012
View article titled, Sorafenib Has Potent Antitumor Activity against Multiple Myeloma <em>In Vitro</em>, <em>Ex Vivo</em>, and <em>In Vivo</em> in the 5T33MM Mouse Model
Open the PDF for Sorafenib Has Potent Antitumor Activity against Multiple Myeloma <em>In Vitro</em>, <em>Ex Vivo</em>, and <em>In Vivo</em> in the 5T33MM Mouse Model in another window
Includes: Supplementary data
Journal Articles

Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma

Sarah Deleu, Miguel Lemaire, Janine Arts, Eline Menu, Els Van Valckenborgh, Isabelle Vande Broek, Hendrik De Raeve, Les Coulton, Ben Van Camp, Peter Croucher, Karin Vanderkerken
Journal: Cancer Research
Cancer Res (2009) 69 (13): 5307–5311.
https://doi.org/10.1158/0008-5472.CAN-08-4472
Published: 01 July 2009
View article titled, Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma
Open the PDF for Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma in another window
Journal Articles

A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model

Eline Menu, Josefina Garcia, Xiangao Huang, Maurizio Di Liberto, Peter L. Toogood, Isan Chen, Karin Vanderkerken, Selina Chen-Kiang
Journal: Cancer Research
Cancer Res (2008) 68 (14): 5519–5523.
https://doi.org/10.1158/0008-5472.CAN-07-6404
Published: 15 July 2008
View article titled, A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model
Open the PDF for A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model in another window
Journal Articles

Inhibition of p38α Mitogen-Activated Protein Kinase Prevents the Development of Osteolytic Bone Disease, Reduces Tumor Burden, and Increases Survival in Murine Models of Multiple Myeloma

Karin Vanderkerken, Satya Medicherla, Les Coulton, Hendrik De Raeve, Angelo Willems, Michelle Lawson, Ben Van Camp, Andrew A. Protter, Linda S. Higgins, Eline Menu, Peter I. Croucher
Journal: Cancer Research
Cancer Res (2007) 67 (10): 4572–4577.
https://doi.org/10.1158/0008-5472.CAN-06-4361
Published: 17 May 2007
View article titled, Inhibition of p38α Mitogen-Activated Protein Kinase Prevents the Development of Osteolytic Bone Disease, Reduces Tumor Burden, and Increases Survival in Murine Models of Multiple Myeloma
Open the PDF for Inhibition of p38α Mitogen-Activated Protein Kinase Prevents the Development of Osteolytic Bone Disease, Reduces Tumor Burden, and Increases Survival in Murine Models of Multiple Myeloma in another window
Journal Articles

An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma

Deborah J. Heath, Karin Vanderkerken, Xin Cheng, Orla Gallagher, Matthew Prideaux, Ramachandran Murali, Peter I. Croucher
Journal: Cancer Research
Cancer Res (2007) 67 (1): 202–208.
https://doi.org/10.1158/0008-5472.CAN-06-1287
Published: 08 January 2007
View article titled, An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma
Open the PDF for An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma in another window
Journal Articles

Delayed in Vivo Disease Progression Is Associated with High Proportions of CD45+ Myeloma Cells in the 5T2MM Murine Model

Kewal Asosingh, Angelo Willems, Ivan Van Riet, Benjamin Van Camp, Karin Vanderkerken
Journal: Cancer Research
Cancer Res (2003) 63 (12): 3019–3020.
Published: 15 June 2003
View article titled, Delayed <em>in Vivo</em> Disease Progression Is Associated with High Proportions of CD45<sup>+</sup> Myeloma Cells in the 5T2MM Murine Model
Open the PDF for Delayed <em>in Vivo</em> Disease Progression Is Associated with High Proportions of CD45<sup>+</sup> Myeloma Cells in the 5T2MM Murine Model in another window
Journal Articles

Recombinant Osteoprotegerin Decreases Tumor Burden and Increases Survival in a Murine Model of Multiple Myeloma

Karin Vanderkerken, Evy De Leenheer, Claire Shipman, Kewal Asosingh, Angelo Willems, Ben Van Camp, Peter Croucher
Journal: Cancer Research
Cancer Res (2003) 63 (2): 287–289.
Published: 15 January 2003
View article titled, Recombinant Osteoprotegerin Decreases Tumor Burden and Increases Survival in a Murine Model of Multiple Myeloma
Open the PDF for Recombinant Osteoprotegerin Decreases Tumor Burden and Increases Survival in a Murine Model of Multiple Myeloma in another window
Journal Articles

A Unique Pathway in the Homing of Murine Multiple Myeloma Cells: CD44v10 Mediates Binding to Bone Marrow Endothelium

Kewal Asosingh, Ursula Günthert, Hendrik De Raeve, Ivan Van Riet, Ben Van Camp, Karin Vanderkerken
Journal: Cancer Research
Cancer Res (2001) 61 (7): 2862–2865.
Published: 01 April 2001
View article titled, A Unique Pathway in the Homing of Murine Multiple Myeloma Cells: <subtitle>CD44v10 Mediates Binding to Bone Marrow Endothelium</subtitle>
Open the PDF for A Unique Pathway in the Homing of Murine Multiple Myeloma Cells: <subtitle>CD44v10 Mediates Binding to Bone Marrow Endothelium</subtitle> in another window
Journal Articles

In Vivo Induction of Insulin-like Growth Factor-I Receptor and CD44v6 Confers Homing and Adhesion to Murine Multiple Myeloma Cells

Kewal Asosingh, Ursula Günthert, Marleen H. C. Bakkus, Hendrik De Raeve, Eva Goes, Ivan Van Riet, Ben Van Camp, Karin Vanderkerken
Journal: Cancer Research
Cancer Res (2000) 60 (11): 3096–3104.
Published: 01 June 2000
View article titled, <em>In Vivo</em> Induction of Insulin-like Growth Factor-I Receptor and CD44v6 Confers Homing and Adhesion to Murine Multiple Myeloma Cells
Open the PDF for <em>In Vivo</em> Induction of Insulin-like Growth Factor-I Receptor and CD44v6 Confers Homing and Adhesion to Murine Multiple Myeloma Cells in another window